Ecnoglutide is a GLP-1 receptor agonist peptide developed by the Chinese biotech Sciwind Biosciences and now commercialized outside China through a partnership with Pfizer. It received approval from China's National Medical Products Administration (NMPA) in 2026, first for type 2 diabetes and shortly after for chronic weight management, making it one of a growing number of GLP-1 drugs to reach the market through China's regulatory system.

How It Works

Like semaglutide and liraglutide, ecnoglutide activates the GLP-1 receptor to reduce appetite and slow gastric emptying. Sciwind describes its mechanism as using a cyclic AMP (cAMP)-based signaling bias, an approach the company says produces steadier receptor activation and may reduce the plateau effect sometimes seen with weight loss on other GLP-1 drugs. That claim comes from the manufacturer and has not been independently confirmed through head-to-head trials against approved GLP-1 drugs, so it should be treated as a marketed hypothesis rather than an established clinical advantage.

What the Trial Data Show

In a 48-week clinical trial, patients receiving the highest tested dose of ecnoglutide achieved average weight loss of about 15.4% from baseline, and roughly 93% of patients reached at least 5% weight loss, a threshold often used to define a clinically meaningful response. These figures are broadly in the same range as approved GLP-1 drugs like semaglutide, though a direct comparison requires a trial that puts both drugs head-to-head in the same population, which has not been conducted.

Regulatory Status

Ecnoglutide, marketed in China as Xianyida for diabetes and Xianweiying for weight management, is approved only through China's NMPA. It is not FDA-approved and is not available by prescription in the United States. Pfizer's deal with Sciwind, reported to be worth up to $495 million in upfront and milestone payments, gives Pfizer commercial rights, while Sciwind retains responsibility for research, manufacturing, and supply. Whether and when Pfizer pursues FDA approval for the U.S. market has not been publicly detailed.

Why It's Part of a Bigger Pattern

Ecnoglutide is one of several GLP-1 peptides that have reached the Chinese market through NMPA approval as domestic and licensed biotechs compete in the same therapeutic space that Novo Nordisk and Eli Lilly currently dominate in the U.S. For patients and clinicians in the U.S., these approvals are worth tracking as pipeline indicators, not as treatments currently accessible through normal prescription channels.

Talk to Your Doctor

Because ecnoglutide has no U.S. regulatory pathway open yet, there is no legitimate source for obtaining it domestically, and any product marketed as ecnoglutide in the U.S. outside a clinical trial should be treated with the same skepticism as any unapproved compound. Patients interested in GLP-1 therapy should discuss FDA-approved options with their physician.

The Bottom Line

Ecnoglutide's approval in China is a reminder that the GLP-1 drug race is now a genuinely global one, with regulatory milestones happening outside the U.S. that can shape which companies and mechanisms eventually compete for FDA approval here. Its eventual path to the U.S. market, if any, remains an open question.